Adjuvant ovarian function suppression and cognitive function in women with breast cancer Academic Article uri icon

Overview

MeSH Major

  • Antineoplastic Agents, Hormonal
  • Breast Neoplasms
  • Ovary
  • Tamoxifen

abstract

  • The Co-SOFT study, although limited by small samples size, provides no evidence that adding OFS to adjuvant oral endocrine therapy substantially affects global cognitive function.

publication date

  • April 26, 2016

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC4984913

Digital Object Identifier (DOI)

  • 10.1038/bjc.2016.71

PubMed ID

  • 27092785

Additional Document Info

start page

  • 956

end page

  • 64

volume

  • 114

number

  • 9